全文获取类型
收费全文 | 153186篇 |
免费 | 32835篇 |
国内免费 | 2392篇 |
专业分类
耳鼻咽喉 | 5193篇 |
儿科学 | 5527篇 |
妇产科学 | 2539篇 |
基础医学 | 3638篇 |
口腔科学 | 1556篇 |
临床医学 | 27052篇 |
内科学 | 48083篇 |
皮肤病学 | 7428篇 |
神经病学 | 15080篇 |
特种医学 | 6498篇 |
外国民族医学 | 1篇 |
外科学 | 41557篇 |
综合类 | 298篇 |
现状与发展 | 72篇 |
一般理论 | 1篇 |
预防医学 | 7339篇 |
眼科学 | 3410篇 |
药学 | 1137篇 |
中国医学 | 13篇 |
肿瘤学 | 11991篇 |
出版年
2024年 | 512篇 |
2023年 | 4781篇 |
2022年 | 1191篇 |
2021年 | 3097篇 |
2020年 | 6026篇 |
2019年 | 2172篇 |
2018年 | 7410篇 |
2017年 | 7348篇 |
2016年 | 8435篇 |
2015年 | 8443篇 |
2014年 | 15513篇 |
2013年 | 15669篇 |
2012年 | 5580篇 |
2011年 | 5568篇 |
2010年 | 10392篇 |
2009年 | 14285篇 |
2008年 | 5886篇 |
2007年 | 4102篇 |
2006年 | 6597篇 |
2005年 | 3895篇 |
2004年 | 3149篇 |
2003年 | 2095篇 |
2002年 | 2201篇 |
2001年 | 3978篇 |
2000年 | 3157篇 |
1999年 | 3349篇 |
1998年 | 3690篇 |
1997年 | 3496篇 |
1996年 | 3406篇 |
1995年 | 3257篇 |
1994年 | 1986篇 |
1993年 | 1592篇 |
1992年 | 1533篇 |
1991年 | 1561篇 |
1990年 | 1179篇 |
1989年 | 1312篇 |
1988年 | 1132篇 |
1987年 | 994篇 |
1986年 | 994篇 |
1985年 | 818篇 |
1984年 | 641篇 |
1983年 | 589篇 |
1982年 | 564篇 |
1981年 | 439篇 |
1980年 | 397篇 |
1979年 | 369篇 |
1978年 | 383篇 |
1977年 | 437篇 |
1975年 | 329篇 |
1972年 | 343篇 |
排序方式: 共有10000条查询结果,搜索用时 922 毫秒
71.
72.
73.
74.
75.
76.
77.
78.
79.
Fiene Marie Kuijper Uma V. Mahajan Seul Ku Daniel A.N. Barbosa Sheila M. Alessi Sherman C. Stein Kyle M. Kampman Brandon S. Bentzley Casey H. Halpern 《Neuromodulation》2022,25(2):253-262
ObjectivesCocaine is the second most frequently used illicit drug worldwide (after cannabis), and cocaine use disorder (CUD)-related deaths increased globally by 80% from 1990 to 2013. There is yet to be a regulatory-approved treatment. Emerging preclinical evidence indicates that deep brain stimulation (DBS) of the nucleus accumbens may be a therapeutic option. Prior to expanding the costly investigation of DBS for treatment of CUD, it is important to ensure societal cost-effectiveness.AimsWe conducted a threshold and cost-effectiveness analysis to determine the success rate at which DBS would be equivalent to contingency management (CM), recently identified as the most efficacious therapy for treatments of CUDs.Materials and MethodsQuality of life, efficacy, and safety parameters for CM were obtained from previous literature. Costs were calculated from a societal perspective. Our model predicted the utility benefit based on quality-adjusted life-years (QALYs) and incremental-cost-effectiveness ratio resulting from two treatments on a one-, two-, and five-year timeline.ResultsOn a one-year timeline, DBS would need to impart a success rate (ie, cocaine free) of 70% for it to yield the same utility benefit (0.492 QALYs per year) as CM. At no success rate would DBS be more cost-effective (incremental-cost-effectiveness ratio <$50,000) than CM during the first year. Nevertheless, as DBS costs are front loaded, DBS would need to achieve success rates of 74% and 51% for its cost-effectiveness to exceed that of CM over a two- and five-year period, respectively.ConclusionsWe find DBS would not be cost-effective in the short term (one year) but may be cost-effective in longer timelines. Since DBS holds promise to potentially be a cost-effective treatment for CUDs, future randomized controlled trials should be performed to assess its efficacy. 相似文献
80.
Status migrainosus is defined by the international classification of headache disorders (ICHD) criteria as a debilitating migraine lasting more then 72 hours. The epidemiology of status migrainosus is still unknown in adult and children, and frequently underdiagnosed. Children and adolescents often end up in the emergency room with an intractable headache that failed outpatient therapy. Six to seven percent of these children do not respond to acute infusion therapy and require hospitalization. It is imperative that more aggressive therapy is considered when patients are affected by a severe intractable headache to prevent further disability and returning the child to baseline activity. Multiple therapies are available for adults and children. Studies for acute therapy in the emergency room are available in adults and pediatric groups. Small studies are available for inpatient therapy in children and, along with available therapies for children and adolescents, are described in this review. A review of the literature shows growing evidence regarding the use of dihydroergotamine intravenously once patients are hospitalized. Effectiveness and safety have been proven in the last decades in adults and small studies in the pediatric populations. 相似文献